VIDEO: 'Super exciting' results of second phase 3 deuruxolitinib trial
Click Here to Manage Email Alerts
NEW ORLEANS — In this Healio exclusive video, Brett King, MD, PhD, discusses highlights from the American Academy of Dermatology Annual Meeting, including results from the second phase 3 trial of deuruxolitinib.
The THRIVE-AA2 double blind, placebo-controlled phase III clinical trial of the oral Janus kinase inhibitor showed that approximately 40% of patients with moderate to severe alopecia areata taking 12 mg deuruxolitinib achieved 20% or less hair loss over 24 weeks of treatment. This was largely in agreement with the first phase 3 trial, King said.
“It’s really rapid improvement in disease in a large proportion of patients, the vast majority of whom achieved 10% or less scalp hair loss during that period of time,” King, associate professor of dermatology at Yale University School of Medicine in New Haven, Connecticut, said.
The findings, King added, are “super exciting.”